Nonetheless, based on the described mechanisms, strategies targeting microglia, employing immune therapies that involve CD4 + and CD8 + T cells, reducing levels of TNF-α and IFN-γ, and suppressing MHC-II-mediated antigen presentation represent potential therapeutic approaches for addressing autoimmunity-induced inflammation in PD.[121]. The gene discussed is TNF; the disease is Parkinson disease.